HCP, Inc. (HCP) Receives $26.70 Average Target Price from Analysts

Shares of HCP, Inc. (NYSE:HCP) have been assigned a consensus rating of “Hold” from the seventeen ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $26.70.

A number of research firms have recently weighed in on HCP. Robert W. Baird upped their target price on HCP from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 9th. Cantor Fitzgerald upped their target price on HCP from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 1st. BMO Capital Markets reiterated a “hold” rating and set a $27.00 target price on shares of HCP in a research report on Wednesday, October 31st. Zacks Investment Research downgraded HCP from a “hold” rating to a “sell” rating in a research report on Tuesday, July 31st. Finally, Morgan Stanley upped their target price on HCP from $23.50 to $25.00 and gave the company an “equal weight” rating in a research report on Thursday, August 16th.

Hedge funds have recently made changes to their positions in the stock. Mount Yale Investment Advisors LLC bought a new stake in shares of HCP during the 2nd quarter worth $104,000. Piedmont Investment Advisors LLC bought a new stake in shares of HCP during the 2nd quarter worth $142,000. Peoples Financial Services CORP. lifted its position in shares of HCP by 87.7% during the 3rd quarter. Peoples Financial Services CORP. now owns 6,100 shares of the real estate investment trust’s stock worth $161,000 after buying an additional 2,850 shares during the last quarter. Wetherby Asset Management Inc. bought a new stake in shares of HCP during the 3rd quarter worth $200,000. Finally, Reliance Trust Co. of Delaware bought a new stake in shares of HCP during the 2nd quarter worth $211,000. Institutional investors and hedge funds own 87.64% of the company’s stock.

Shares of NYSE HCP opened at $28.72 on Monday. The company has a current ratio of 0.48, a quick ratio of 0.48 and a debt-to-equity ratio of 1.21. HCP has a one year low of $21.48 and a one year high of $28.73. The firm has a market capitalization of $13.39 billion, a price-to-earnings ratio of 14.73, a PEG ratio of 7.15 and a beta of 0.16.

HCP (NYSE:HCP) last issued its quarterly earnings data on Wednesday, October 31st. The real estate investment trust reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.10. HCP had a return on equity of 3.06% and a net margin of 9.16%. The firm had revenue of $456.00 million for the quarter, compared to analyst estimates of $456.59 million. During the same period in the prior year, the firm posted $0.48 EPS. The company’s revenue for the quarter was up .4% on a year-over-year basis. Equities analysts forecast that HCP will post 1.82 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 20th. Stockholders of record on Monday, November 5th will be given a dividend of $0.37 per share. The ex-dividend date is Friday, November 2nd. This represents a $1.48 dividend on an annualized basis and a dividend yield of 5.15%. HCP’s payout ratio is 75.90%.

About HCP

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Featured Story: How to Invest in Marijuana Stocks

Analyst Recommendations for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply